Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11026847 | PMC |
| http://dx.doi.org/10.3389/fimmu.2024.1407748 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial: Biologic drugs in immune-mediated inflammatory diseases, validation, drug-utilization, effectiveness, regulation, costs, and safety in the real-world.
Front Pharmacol
January 2025
Department of Diagnostic and Public Health, Section of Pharmacology, University of Verona, Verona, Italy.
The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis.
Front Immunol
January 2025
Department of Neurosciences, University of Padua, Padua, Italy.
Pediatric-Onset Multiple Sclerosis (POMS) is characterized by both white and grey matter inflammation, as well as by a higher risk of long-term physical and cognitive disability. The peculiar immunopathogenic mechanisms of POMS suggests that the use of induction therapies, including alemtuzumab (ALTZ), might be a promising approach, at least for postpuberal (> 11 yo) POMS. Although no data on the use of induction therapies in POMS are available from clinical trials currently, case series or case reports on the effect of alemtuzumab (ALTZ) have been recently published.
View Article and Find Full Text PDFAn update on oral manifestations of systemic disorders in dogs and cats.
Front Vet Sci
January 2025
School of Veterinary Medicine, Veterinary Surgical and Radiological Sciences, University of California, Davis, Davis, CA, United States.
Oral lesions are common in dogs and cats, and determining the underlying etiology of these lesions can be challenging. A wide range of systemic ailments may lead to lesions in the oral cavity, including immune-mediated diseases, adverse drug reactions, viral and bacterial infections, and metabolic and autoimmune diseases. A complete history and thorough physical examination (including a fundic examination) should be obtained in affected patients.
View Article and Find Full Text PDFHeart to Heal: Unveiling Follistatin's Potential for Myocardial Regeneration.
Circ Res
January 2025
Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Germany (A.C., C.B.).
Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study.
Dermatol Ther (Heidelb)
January 2025
Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle Marche, Ancona, Italy.
Introduction: Psoriasis is characterized by aberrant keratinocyte activity and immune cell infiltration, driven by immune-mediated pathways. MicroRNAs (miRNAs) play crucial roles in regulating these processes, offering insights into disease mechanisms and therapeutic targets.
Objectives: This study aimed to investigate changes in circulating miRNAs in psoriasis patients undergoing risankizumab therapy, an anti-IL-23 monoclonal antibody, to understand its impact on disease pathogenesis and treatment response.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!